- •To detect the effect of young age on survival in ovarian cancer patients.
- •A meta-database analysis of 5055 ovarian cancer patients.
- •Potential confounding and effect measure modification are considered.
- •Prognostic factors of survival are similar in patients under and over 40 years of age.
- •Young age at diagnosis of ovarian cancer improves survival.
We evaluated in a large study meta-database of prospectively randomised phase III trials the prognostic factors for progression-free survival (PFS) and overall survival (OS) in patients < and >40 years of age with advanced epithelial ovarian cancer.
A total of 5055 patients of the AGO, GINECO, NSGO intergroup studies AGO-OVAR 3, 5, 7 and 9 were merged to identify 294 patients <40 years and 4761 patients ≥40 years. We conducted survival analyses and Cox proportional hazard regression models and additionally analysed a very homogeneous subcohort of 405 patients with serous epithelial ovarian cancer, excellent performance status, who had received complete macroscopic upfront cytoreduction and ≥5 chemotherapy cycles.
For patients <40 years, the median PFS was 28.9 months and the median OS was 75.3 months, while the median PFS for patients ≥40 years was 18.1 months and the median OS was 45.7 months. Independent prognostic factors were similar in both age groups. In a multivariate analysis including prognostic factors potentially leading to confounding, young age appeared to improve PFS (hazard ratio [HR], 0.86; 95% confidence interval [CI]: 0.72–1.03) and OS (HR, 0.73; 95% CI: 0.59–0.91). The observed effect was even stronger in the subcohort of optimally treated patients with SEOC: PFS (HR, 0.34; 95% CI: 0.19–0.59) and OS (HR, 0.23; 95% CI: 0.09–0.56).
Prognostic factors were similar in both age groups. Young age appeared a strong independent protective prognostic factor for PFS and OS in the subcohort.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study.Lancet Oncol. 2013; https://doi.org/10.1016/S1470-2045(13)70546-1
- Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.J Clin Oncol. 2007; 25: 3621-3627https://doi.org/10.1200/JCO.2006.10.2517
- Ovarian cancer: epidemiology, biology, and prognostic factors.Semin Surg Oncol. 2000; 19: 3-10
- Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.J Cancer Res Clin Oncol. 2013; 139: 1257-1277https://doi.org/10.1007/s00432-013-1435-z
- Age as prognostic factor in premenopausal breast carcinoma.Lancet. 1993; 341: 1039-1043
- Breast carcinomas occurring in young women (< 35 years) are different.Br J Cancer. 1996; 74: 1796-1800
- Factors influencing the effect of age on prognosis in breast cancer: population based study.BMJ. 2000; 320: 474-478
Cancer statistics review, 1975-2010-SEER statistics. Available at: http://seer.cancer.gov/csr/1975_2010/. [accessed 27.03.14].
- Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.J Natl Cancer Inst. 2006; 98: 1036-1045https://doi.org/10.1093/jnci/djj296
- A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.J Natl Cancer Inst. 2003; 95: 1320-1329
- Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.J Clin Oncol. 2006; 24: 1127-1135https://doi.org/10.1200/JCO.2005.03.2938
- Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.J Clin Oncol. 2010; 28: 4162-4169https://doi.org/10.1200/JCO.2009.27.4696
- Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality.Cancer. 1993; 71: 517-523
- Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).Gynecol Oncol. 2006; 100: 300-307https://doi.org/10.1016/j.ygyno.2005.08.029
- Ovarian cancer in the elderly.Crit Rev Oncol Hematol. 2004; 49: 77-86
- National survey of ovarian carcinoma. IV: patterns of care and related survival for older patients.Cancer. 1994; 73: 377-383
- Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients.Gynecol Oncol. 2012 Nov; 127: 367-374
- Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience.Oncology. 2006; 70: 265-272https://doi.org/10.1159/000094889
- Epithelial ovarian carcinoma in the reproductive age group.Cancer. 1999; 85: 2623-2629
- Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor.Cancer. 1996; 77: 1131-1136
- Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience.Cancer. 1993; 71: 606-614
- Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy.Eur J Cancer. 1999; 35: 727-732
- Physical activity in different periods of life, sedentary behavior, and the risk of ovarian cancer in the NIH-AARP diet and health study.Cancer Epidemiol Biomarkers Prev. 2013; 22: 2000-2008https://doi.org/10.1158/1055-9965.EPI-13-0154
- Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation.BMC Med Inform Decis Mak. 2013; 13: 72https://doi.org/10.1186/1472-6947-13-72
- The genetic attributable risk of breast and ovarian cancer.Cancer. 1996; 77: 2318-2324https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z
- BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III–IV) ovarian cancer.Int J Gynecol Cancer. 2014 Oct; 24: 1395-1400
- BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.J Clin Oncol. 2012 Jul 20; 30: 2654-2663
- Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1).J Clin Oncol. 2016; 34 (suppl; abstr 5538)
- Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.J Clin Oncol. 1991; 9: 1138-1150
- Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.Int J Gynecol Cancer. 2010; 20: 945-952https://doi.org/10.1111/IGC.0b013e3181dd0110
Published online: August 25, 2016
Accepted: July 5, 2016
Received in revised form: July 4, 2016
Received: April 14, 2016
© 2016 Elsevier Ltd. All rights reserved.